In today’s trading session, several stocks are poised to capture investor attention due to significant developments. With a mix of renewable energy initiatives, strategic asset sales, and pharmaceutical advancements, these companies are making headlines. Let’s delve into the key players and their latest movements in the market.

Tata Power’s Major Renewable Energy Venture

Tata Power Renewable Energy, a key subsidiary of Tata Power, has recently signed a Memorandum of Understanding (MoU) with the Government of Andhra Pradesh. This partnership aims to establish an ambitious portfolio of renewable energy projects, targeting up to 7,000 MW. The projects will encompass a range of solutions, including solar, wind, and hybrid systems, with options for energy storage. The investment for these groundbreaking initiatives is projected to reach ₹49,000 crore, marking a significant step toward sustainable energy in India.

Nazara Technologies Divests Stake in OpenPlay

In a strategic move, Nazara Technologies has divested a 94.85% stake in OpenPlay Technologies to Moonshine Technology for ₹104.33 crore. This transaction will be executed through the issuance of compulsory convertible preference shares (CCPS) to Nazara and other stakeholders. OpenPlay Technologies is renowned for its popular rummy platform, Classic Rummy, while Moonshine is the parent company of PokerBaazi, the leading poker platform in India.

RailTel Wins New Contracts

RailTel Corporation has announced a significant achievement, securing a work order valued at ₹28.29 crore from Northern Railway. This order is for comprehensive indoor and outdoor double distant signaling work. Furthermore, the board will convene on March 12 to evaluate a potential second interim dividend for FY25. Additionally, RailTel has received another substantial work order worth ₹47.50 crore from East Central Railway.

Lupin Launches New Cardiac Drug

Lupin Pharmaceuticals has made strides in the U.S. market by introducing Rivaroxaban tablets (USP, 2.5 mg), following the final approval of its Abbreviated New Drug Application by the US FDA. This medication is bioequivalent to Janssen Pharmaceuticals’ Xarelto, designed to reduce the risk of major cardiovascular events in patients suffering from coronary artery disease, as well as thrombotic vascular events in those with peripheral artery disease.

NMDC Board Meeting on Interim Dividend

The NMDC board is set to meet on March 17 to discuss the possibility of declaring an interim dividend for FY25. This meeting could have significant implications for shareholders, so investors will be keenly observing the outcomes.

Hinduja Global’s Strategic Merger

After receiving the green light from the Philippine Securities and Exchange Commission, Hinduja Global Solutions announced the merger of its step-down subsidiary, Diversify Intelligent Staffing Solutions Inc., with another subsidiary, Diversify ISS BGC Inc. This merger led to the dissolution of Diversify Intelligent Staffing Solutions Inc. as of March 7, 2025, streamlining the company’s operations.

Expansion at GMR Airports

GMR Airports has expanded its stake in Delhi International Airport (DIAL) by acquiring an additional 10% from Fraport AG Frankfurt Airport Services Worldwide. This acquisition boosts GMR’s ownership in DIAL from 64% to 74%, enhancing its influence over one of India’s busiest airports.

Shilpa Medicare Under FDA Scrutiny

The USFDA recently conducted an inspection at Shilpa Medicare’s Unit-1 in Raichur from March 3 to 7, 2025. Following the inspection, the company received a single observation in Form 483, which is a standard procedural notice.

JSW Steel Reports Production Growth

JSW Steel recorded a notable increase in its consolidated crude steel production, achieving 24.07 lakh tonnes in February 2025. This figure represents a 12% increase compared to 21.50 lakh tonnes in February 2024. The company also reported an impressive capacity utilization rate of 93.5% across its Indian operations during the month.

AstraZeneca Gains Approval for Cancer Drug

AstraZeneca Pharma has received approval from the Central Drugs Standard Control Organisation to import, sell, and distribute Durvalumab solution in India. This medication is aimed at treating patients with limited-stage small cell lung cancer (LS-SCLC), allowing the company to market Durvalumab for infusion in 120 mg/2.4 ml and 500 mg/10 ml (branded as Imfinzi).

Gensol Engineering Considers Stock Split

The board of Gensol Engineering is set to discuss a proposed stock split, which would reduce the face value of its shares from ₹10. This meeting is scheduled for March 13, and the decision could significantly impact the stock’s liquidity and market perception.

These developments are pivotal for investors and market watchers, highlighting the dynamic nature of the current trading landscape. Keep an eye on these companies as they navigate their respective paths in the evolving market.